In our recent review analyzing BCR::ABL1/JAK2 V617F double-positive cases, the majority of patients fell into the group of JAK2-mutated MPN preceding CML (49.42%) (Zanelli et al., 2024). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.